德琪医药-B(06996)：希维奥®在香港获批用于治疗多发性骨髓瘤及弥漫大B细胞淋巴瘤两种新增适应症

智通财经12-03 16:38

智通财经APP讯，德琪医药-B(06996)公布，香港特别行政区政府卫生署已批准希维奥^® (塞利尼索)的两项补充新药上市申请(sNDA)，批准希维奥^®联合硼替佐米和地塞米松(XVd)用于治疗既往接受过至少一种治疗的多发性骨髓瘤(MM)成年患者;及希维奥^®作为单药用于治疗复发性或难治性弥漫大B细胞淋巴瘤(rrDLBCL)成人患者，除另有说明外，其包含接受过至少两线系统性治疗且不符合造血干细胞移植的由滤泡性淋巴瘤引起的弥漫大B细胞淋巴瘤(DLBCL)。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2588019668?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-03 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588019668","market":"hk","top_or_hot":-1,"title":"德琪医药-B(06996)：希维奥®在香港获批用于治疗多发性骨髓瘤及弥漫大B细胞淋巴瘤两种新增适应症","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06996\">德琪医药-B</a>(06996)公布，香港特别行政区政府卫生署已批准希维奥<sup>®</sup> (塞利尼索)的两项补充新药上市申请(sNDA)，批准希维奥<sup>®</sup>联合硼替佐米和地塞米松(XVd)用于治疗既往接受过至少一种治疗的多发性骨髓瘤(MM)成年患者;及希维奥<sup>®</sup>作为单药用于治疗复发性或难治性弥漫大B细胞淋巴瘤(rrDLBCL)成人患者，除另有说明外，其包含接受过至少两线系统性治疗且不符合造血干细胞移植的由滤泡性淋巴瘤引起的弥漫大B细胞淋巴瘤(DLBCL)。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德琪医药-B(06996)：希维奥®在香港获批用于治疗多发性骨髓瘤及弥漫大B细胞淋巴瘤两种新增适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德琪医药-B(06996)：希维奥®在香港获批用于治疗多发性骨髓瘤及弥漫大B细胞淋巴瘤两种新增适应症\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2025-12-03 16:38</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06996\">德琪医药-B</a>(06996)公布，香港特别行政区政府卫生署已批准希维奥<sup>®</sup> (塞利尼索)的两项补充新药上市申请(sNDA)，批准希维奥<sup>®</sup>联合硼替佐米和地塞米松(XVd)用于治疗既往接受过至少一种治疗的多发性骨髓瘤(MM)成年患者;及希维奥<sup>®</sup>作为单药用于治疗复发性或难治性弥漫大B细胞淋巴瘤(rrDLBCL)成人患者，除另有说明外，其包含接受过至少两线系统性治疗且不符合造血干细胞移植的由滤泡性淋巴瘤引起的弥漫大B细胞淋巴瘤(DLBCL)。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1377039.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1377039.html","article_id":"2588019668","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588019668","pubTimestamp":1764751139,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，德琪医药-B(06996)公布，香港特别行政区政府卫生署已批准希维奥® (塞利尼索)的两项补充新药上市申请(sNDA)，批准希维奥®联合硼替佐米和地塞米松(XVd)用于治疗既往接受过至少一种治疗的多发性骨髓瘤(MM)成年患者;及希维奥®作为单药用于治疗复发性或难治性弥漫大B细胞淋巴瘤(rrDLBCL)成人患者，除另有说明外，其包含接受过至少两线系统性治疗且不符合造血干细胞移植的由滤泡性淋巴瘤引起的弥漫大B细胞淋巴瘤(DLBCL)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","06996":"德琪医药-B","BK1574":"生物医药B类股"},"translate_title":"Antengene-B (06996): Sivio ® Approved in Hong Kong for the treatment of multiple myeloma and diffuse large B-cell lymphoma in two new indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1.5},"content_text":"智通财经APP讯，德琪医药-B(06996)公布，香港特别行政区政府卫生署已批准希维奥® (塞利尼索)的两项补充新药上市申请(sNDA)，批准希维奥®联合硼替佐米和地塞米松(XVd)用于治疗既往接受过至少一种治疗的多发性骨髓瘤(MM)成年患者;及希维奥®作为单药用于治疗复发性或难治性弥漫大B细胞淋巴瘤(rrDLBCL)成人患者，除另有说明外，其包含接受过至少两线系统性治疗且不符合造血干细胞移植的由滤泡性淋巴瘤引起的弥漫大B细胞淋巴瘤(DLBCL)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588019668","isCrawlerRequest":true}